

**DANEKER, McINTIRE, SCHUMM, PRINCE,
GOLDSTEIN, MANNING & WIDMANN, P.C.**

Blaustein Building, Suite 2450

One N. Charles St.

Baltimore, MD 21201

(410) 649-4747

Facsimile: (410) 649-4758

FACSIMILE NO.: (410) 649-4758**OFFICIAL****RECEIVED
CENTRAL FAX CENTER****SEP 29 2003****FACSIMILE COVER SHEET****IMPORTANT NOTICE**

PLEASE DELIVER THE FOLLOWING MATERIAL AS SOON AS POSSIBLE TO:

COMPANY: U.S. Patent and Trademark Office**ATTENTION:** Examiner Jerome Goldberg**RECIPIENT FAX NUMBER:** (703) 872-9306 (Official Fax)**FROM:** Brooke Schumm III**DIRECT DIAL:** (410) 649-4761**NUMBER OF PAGES:** (Including Cover Sheet)**DATE TRANSMITTED:** September 26, 2003 (4:49PM)**PHONE NUMBER TO VERIFY MESSAGE RECEIVED:** (410) 649-4747

S/N 09/997,490

Thank you for your attention and assistance.

FILE NO.: walter-PBC**NOTE:** Hard copy to follow by mail? Yes ☐ No ☒

The information contained in this facsimile message is attorney-privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the recipient, you are notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to the above address via the U.S. Postal Service. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Inventors George Kindness
Brooke Schumm III
F. Timothy Guilford

:

Group Art Unit: 1614

:

Appl. No. 09/997,490

:

Examiner: Jerome D. Goldberg

Filed: November 17, 2001

:

For: A COMBINATION AND METHOD OF TREATMENT OF CANCER
UTILIZING A COX-2 INHIBITOR AND A 3-HYDROXY-3-METHYLGLUTARYL-
COENZYME-A (HMG-CoA) REDUCTASE INHIBITOR

CONTINUATION IN PART OF PROVISIONAL APPLICATION 60/245,592 FILED
November 17, 2000, AND PROVISIONAL APPLICATION 60/264,511 filed January 26, 2001,
and PROVISIONAL APPLICATION 60/307,689 filed July 25, 2001

To: Assistant Commissioner of Patents
Alexandria, VA 22313-1450

ELECTION OF CLAIMS

Applicants make election to the invention(s) proposing the composition of a glutathione pathway enhancing and detoxifying compound, in particular cystine, combined with a selective COX-2 inhibitor and a statin. This includes claims 2, and 3, and 4, 5 and 6. Further included are claims 11, 12, and 13 which are multiply dependent on claims 1-10, but election here would be to those claims only as they depend on claims 2-6. Based on the examiner's comments in the telephone interview, election as set forth in the first paragraph appeared acceptable.

The examiner is authorized to make the amendment by interlineation. Such interlineation is striking the characters "--1-10--" in claim 11 and inserting in their place "--2-6--", striking the

characters "--1-10--" in claim 12 and inserting in their place "--2-6--", and striking the characters "--1-10--" in claim 13 and inserting in their place "--2-6--". Alternatively, if a preliminary amendment is needed on claims 11,12, or 13, Applicants will submit one shortly.

Applicants submit that statins are generally looked upon as a group of similarly acting compounds: that is 3-HMG CoA Reductase Inhibitors.

Applicants submit that selective COX-2 inhibitors are also generally looked upon as a group of similarly acting compounds with selective inhibition of the COX-2 biochemical pathway in preference to the inhibition of the COX-1 biochemical pathway.

A reference that cites the latter statins as a group and generally interchangeable within that group, and selective COX-2 inhibitors as a group and generally interchangeable within that group is, "Goodman & Gilman's The Pharmacologic Basis of Therapeutics (9th ed. McGraw-Hill 1996).

A substantial number of other patents have been allowed citing classes of statins and selective COX-2 inhibitors including Winokur, 6,245,797, June 12, 2001.

If the examiner does not believe that the class grouping is reasonable as done in pharmaceutical guides, election with traverse is made on use of statins and selective COX-2 inhibitors as a group. If the examiner requires a single compound of the class of statins and a single compound of the class of selective COX-2 inhibitors be selected, then applicants would

elect celecoxib and atorvastatin. Again, based on the examiner's comments, election as set forth in the first paragraph appeared acceptable.

Examiner Goldberg is respectfully thanked for his suggestions and wished a successful retirement.

RECEIVED
CENTRAL FAX CENTER

SEP 29 2003

Date:

9/26/2003

Respectfully submitted,

Brooke Schumm III

Brooke Schumm III

Pat. Atty. #34,926

Danecker, McIntire, Schumm, Prince

Goldstein, Manning & Widmann, P.C.

One N. Charles St.

24th floor

Baltimore, MD 21201

(410) 649-4761

on behalf of Applicants

ICIAL

CERTIFICATE OF SERVICE

I certify I caused a copy of the above Election to be telecopied by facsimile machine to (703) 872-9306 on this 26th day of September, 2003, to the Assistant Commissioner of Patents, Examiner Goldberg, Group Art Unit 1614, Washington DC 20231.

Brooke Schumm III
Brooke Schumm III

Date 9/26/2003